FDA Approves AstraZeneca Blood Pressure Drug Baxfendy
The U.S. FDA has approved AstraZeneca's Baxfendy for patients with uncontrolled high blood pressure despite existing treatments. The drug targets aldosterone production and is expected to reach peak annual sales of over $5 billion following its acquisition from CinCor Pharma.
Xurve View
Insights:
Xurve View
ASTRAZENECA PLC secured United States approval for its hypertension pill Baxfendy, which the drugmaker expects to generate $5 billion in peak annual sales. The decision follows the $1.8 billion acquisition of CinCor Pharma in February 2023 to expand the cardiovascular portfolio. It provides a new revenue stream addressing 120 million Americans with uncontrolled high blood pressure despite existing treatments.
